Edwards Lifesciences Co. (NYSE:EW) Shares Acquired by Lido Advisors LLC

Lido Advisors LLC lifted its position in shares of Edwards Lifesciences Co. (NYSE:EW) by 10.4% in the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 18,178 shares of the medical research company’s stock after buying an additional 1,710 shares during the period. Lido Advisors LLC’s holdings in Edwards Lifesciences were worth $1,715,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds and other institutional investors have also made changes to their positions in the company. Castleview Partners LLC acquired a new stake in shares of Edwards Lifesciences during the 1st quarter worth approximately $25,000. Altshuler Shaham Ltd acquired a new stake in Edwards Lifesciences in the 2nd quarter valued at approximately $31,000. Northwest Capital Management Inc acquired a new stake in Edwards Lifesciences in the 2nd quarter valued at approximately $34,000. Jones Financial Companies Lllp acquired a new stake in Edwards Lifesciences in the 1st quarter valued at approximately $33,000. Finally, Compass Wealth Management LLC acquired a new stake in Edwards Lifesciences in the 4th quarter valued at approximately $31,000. Institutional investors and hedge funds own 79.25% of the company’s stock.

Analysts Set New Price Targets

EW has been the subject of several research reports. Mizuho dropped their target price on shares of Edwards Lifesciences from $90.00 to $85.00 and set a “buy” rating for the company in a report on Thursday, October 26th. Truist Financial dropped their target price on shares of Edwards Lifesciences from $83.00 to $76.00 and set a “buy” rating for the company in a report on Thursday, October 26th. Jefferies Financial Group lifted their target price on shares of Edwards Lifesciences from $103.00 to $107.00 and gave the company a “buy” rating in a report on Tuesday, July 25th. Piper Sandler dropped their target price on shares of Edwards Lifesciences from $83.00 to $68.00 and set a “neutral” rating for the company in a report on Thursday, October 26th. Finally, TheStreet downgraded shares of Edwards Lifesciences from a “b-” rating to a “c+” rating in a research note on Wednesday, August 9th. One research analyst has rated the stock with a sell rating, ten have given a hold rating and eight have issued a buy rating to the company. According to MarketBeat, the company presently has a consensus rating of “Hold” and a consensus price target of $84.29.

Insider Buying and Selling at Edwards Lifesciences

In other Edwards Lifesciences news, Director Michael A. Mussallem sold 29,350 shares of the company’s stock in a transaction that occurred on Tuesday, September 5th. The stock was sold at an average price of $75.86, for a total transaction of $2,226,491.00. Following the completion of the sale, the director now directly owns 4,486 shares of the company’s stock, valued at approximately $340,307.96. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. In other Edwards Lifesciences news, CFO Scott B. Ullem sold 7,255 shares of the company’s stock in a transaction that occurred on Tuesday, October 31st. The stock was sold at an average price of $62.66, for a total transaction of $454,598.30. Following the completion of the sale, the chief financial officer now directly owns 19,248 shares of the company’s stock, valued at approximately $1,206,079.68. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Michael A. Mussallem sold 29,350 shares of the company’s stock in a transaction that occurred on Tuesday, September 5th. The shares were sold at an average price of $75.86, for a total value of $2,226,491.00. Following the sale, the director now directly owns 4,486 shares of the company’s stock, valued at $340,307.96. The disclosure for this sale can be found here. Insiders sold a total of 179,795 shares of company stock valued at $12,724,914 in the last ninety days. Insiders own 1.29% of the company’s stock.

Edwards Lifesciences Stock Up 1.9 %

Edwards Lifesciences stock opened at $67.01 on Thursday. Edwards Lifesciences Co. has a fifty-two week low of $60.57 and a fifty-two week high of $94.87. The company has a debt-to-equity ratio of 0.09, a quick ratio of 2.45 and a current ratio of 3.28. The company has a market capitalization of $40.64 billion, a P/E ratio of 28.64, a PEG ratio of 3.60 and a beta of 1.02. The stock has a 50-day simple moving average of $69.40 and a 200-day simple moving average of $79.88.

Edwards Lifesciences (NYSE:EW) last posted its earnings results on Wednesday, October 25th. The medical research company reported $0.59 earnings per share for the quarter, meeting the consensus estimate of $0.59. Edwards Lifesciences had a return on equity of 24.54% and a net margin of 24.59%. The business had revenue of $1.48 billion during the quarter, compared to the consensus estimate of $1.48 billion. During the same period in the previous year, the business earned $0.61 EPS. The business’s quarterly revenue was up 12.3% on a year-over-year basis. Equities research analysts expect that Edwards Lifesciences Co. will post 2.51 earnings per share for the current year.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease, and critical care and surgical monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of heart valves; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases.